Status:
UNKNOWN
Therapeutic Drug Monitoring of Anti-infectious Drugs in Intensive Care Unit
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Infection, Bacterial
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research targets four anti-infectives commonly prescribed in intensive care: ceftazidime, cefepime, cefotaxime and meropenem, used for severe infections For patient hospitalized in intensive care...
Detailed Description
Antibiotics, and especially beta-lactams, are among the most used drugs in the world. The good use of antibiotics and the prevention of selection of resistant strains has been a public health priority...
Eligibility Criteria
Inclusion
- Adult patient (age\> 18 years)
- Patient hospitalized in intensive care for a duration greater than 7 days, treated with cefotaxime, ceftazidime, cefepime, piperacillin or meropenem according to a standardized dosing regimen.
Exclusion
- Age \<18
- Pregnant woman
- Patient allergic to beta-lactams
- No written informed consent by the patient or his/her (legal) representative
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03339869
Start Date
January 2 2018
End Date
October 31 2020
Last Update
November 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.